As Rituxan biosimilar competition hots up, Genentech starts legal in action in Japan

11 January 2018

Genentech has filed a lawsuit in the Tokyo District Court in a bit to prohibit sales of a biosimilar product of antiCD20 monoclonal antibody Rituxan (rituximab), marketed in Europe as MabThera.

Swiss pharma giant Roche’s (ROG: SIX) biotech arm filed the suit against Novartis (NOVN: VX) subsidiary Sandoz, the manufacturer and distributor, and Tokyo-based Kyowa Hakko Kirin (TYO: 4151), the local distributor.

Japan’s Ministry of Health, Labor and Welfare approved the product in late September last year.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK